The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma : Episode 7
Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options
This video episode compares ide-cel and cilta-cel for patient selection, examining specific characteristics, efficacy and safety profiles, and their influence on treatment decisions across diverse patient groups.
EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel
EP: 2.Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting
EP: 3.Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma
EP: 4.Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel
EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel
EP: 6.Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert
Now Viewing
EP: 7.Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options
Video content above is prompted by the following:
- How would you compare ide-cel and cilta-cel in terms of patient selection?
- Are there specific patient characteristics that might make you lean towards one CAR-T product over the other?
- How do the efficacy and safety profiles of these two products influence your decision-making for different patient groups?
Recent Videos
Related Content
